Literature DB >> 18270270

Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer.

Arezoo Astanehe1, David Arenillas, Wyeth W Wasserman, Peter C K Leung, Sandra E Dunn, Barry R Davies, Gordon B Mills, Nelly Auersperg.   

Abstract

Inactivation of the transcription factor and tumor suppressor p53, and overexpression or mutational activation of PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol-3-kinase (PI3K), are two of the most common deleterious genomic changes in cancer, including in ovarian carcinomas. We investigated molecular mechanisms underlying interactions between these two mediators and their possible roles in ovarian tumorigenesis. We identified two alternate PIK3CA promoters and showed direct binding of and transcriptional inhibition by p53 to one of these promoters. Conditional suppression of functional p53 increased p110alpha transcripts, protein levels and PI3K activity in immortalized, non-tumorigenic ovarian surface epithelial (OSE) cells, the precursors of ovarian carcinoma. Conversely, overexpression of p53 by adenoviral infection and activation of p53 by gamma-irradiation both diminished p110alpha protein levels in normal OSE and ovarian cancer cells. The demonstration that p53 binds directly to the PIK3CA promoter and inhibits its activity identifies a novel mechanism whereby these two mediators regulate cellular functions, and whereby inactivation of p53 and subsequent upregulation of PIK3CA might contribute to the pathophysiology of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270270     DOI: 10.1242/jcs.013029

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  37 in total

1.  p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

Authors:  Bhushan Thakur; Pritha Ray
Journal:  Mol Oncol       Date:  2016-06-29       Impact factor: 6.603

2.  Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.

Authors:  Sutapa Sinha; Krishnendu Pal; Ahmed Elkhanany; Shamit Dutta; Ying Cao; Gourish Mondal; Seethalakshmi Iyer; Veena Somasundaram; Fergus J Couch; Viji Shridhar; Resham Bhattacharya; Debabrata Mukhopadhyay; Priya Srinivas
Journal:  Int J Cancer       Date:  2012-07-27       Impact factor: 7.396

3.  A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer.

Authors:  Bo Pang; Shi-Peng Sun; Lei Gao; Rui-Li Zhu; Li-xin Zhang; Cheng An; Zhi-Yuan Liu; Gui-Jian Liu
Journal:  Med Oncol       Date:  2014-06-08       Impact factor: 3.064

4.  Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.

Authors:  Lisa K Mullany; Zhilin Liu; Erin R King; Kwong-Kwok Wong; JoAnne S Richards
Journal:  Endocrinology       Date:  2012-03-06       Impact factor: 4.736

5.  Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.

Authors:  Michael G Woo; Kai Xue; Jiayin Liu; Heidi McBride; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2011-11-23       Impact factor: 5.157

6.  Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.

Authors:  Canan Schumann; Stephanie Chan; Oleh Khalimonchuk; Shannon Khal; Vitaliya Moskal; Vidhi Shah; Adam W G Alani; Olena Taratula; Oleh Taratula
Journal:  Mol Pharm       Date:  2016-05-26       Impact factor: 4.939

7.  PIK3CA alterations in Middle Eastern ovarian cancers.

Authors:  Jehad Abubaker; Prashant Bavi; Wael Al-Haqawi; Zeenath Jehan; Adnan Munkarah; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2009-07-28       Impact factor: 27.401

8.  The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Authors:  Ryan T Anderson; Stephen B Keysar; Daniel W Bowles; Magdalena J Glogowska; David P Astling; J Jason Morton; Phuong Le; Adrian Umpierrez; Justin Eagles-Soukup; Gregory N Gan; Brian W Vogler; Daniel Sehrt; Sarah M Takimoto; Dara L Aisner; Francois Wilhelm; Barbara A Frederick; Marileila Varella-Garcia; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

9.  Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells.

Authors:  Trang H Luu; Jean-Marie Bard; Delphine Carbonnelle; Chloé Chaillou; Jean-Michel Huvelin; Christine Bobin-Dubigeon; Hassan Nazih
Journal:  Cell Oncol (Dordr)       Date:  2017-10-09       Impact factor: 6.730

10.  Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.

Authors:  Shun Liang; Nuo Yang; Yue Pan; Shan Deng; Xiaojuan Lin; Xiaojun Yang; Dionyssios Katsaros; Katherine F Roby; Thomas C Hamilton; Denise C Connolly; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2009-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.